Major depressive disorder (MDD) is a debilitating illness characterized by neuroanatomical
and functional alterations in limbic structures, notably the prefrontal cortex (PFC), that can be …

Recently designated as a disorder in the DSM-5, premenstrual dysphoric disorder (PMDD)
presents an array of avenues for further research. PMDD's profile, characterized by cognitive …

Dehydroepiandrosterone (DHEA) and cortisol are the most abundant hormones of the
human fetal and adult adrenals released as end products of a tightly coordinated endocrine …

Objective: In this conceptual review, the authors propose a novel mechanistic candidate in
the etiology of depression with onset in the menopause transition (“perimenopausal …

Premenstrual dysphoric disorder (PMDD) is a severe mood disorder with core symptoms
(affective lability, irritability, depressed mood, anxiety) and increased sensitivity to stress …

Women worldwide are two to three times more likely to suffer from depression in their
lifetime than are men. Female risk for depressive symptoms is particularly high during the …

Objective: Concurrent anxiety and/or insomnia symptoms in women with postpartum
depression (PPD) are common and associated with more severe PPD. The effects of …

Recent FDA approval of an allopregnanolone-based treatment specifically for postpartum
depression, brexanolone, now commercially called Zulresso®, is an exciting development …

The aim of this narrative review is to consolidate knowledge on the role of the hypothalamic-
pituitary-adrenal (HPA) axis in depression pathophysiology at different reproductive stages …

Stress and previous adverse life events are well-established risk factors for depression.
Further, neuroendocrine disruptions are associated with both major depressive disorder …